Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis

IntroductionThis meta-analysis aimed to evaluate the efficacy and safety of Lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors (PD-1 inhibitors) in the treatment of intermediate or advanced hepatocellular carcinoma (HCC).Materials and MethodsFour databases...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yongfa Lei, Xiaotian Liang, Hua Zhu, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-07-01
Serija:	Frontiers in Immunology
Teme:	hepatocellular carcinoma lenvatinib PD-1 inhibitor transarterial chemoembolization progression-free survival overall survival
Online pristup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586914/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!